who we are: atai is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. our mission: we are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. our approach: by pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based treatments.
Company profile
Ticker
ATAI
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ATAI Life Sciences B.V.
SEC CIK
Corporate docs
Subsidiaries
Atai Holdco, Inc. • Atai Life Sciences US, Inc. • Atai Life Sciences AG • Atai Life Sciences UK Ltd • Atai Therapeutics, Inc. • DemeRx IB, Inc. • EmpathBio, Inc. • EntheogeniX Biosciences, Inc. • GABA Therapeutics, Inc. • InnarisBio, Inc. ...
ATAI stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
15 May 24
8-K
Results of Operations and Financial Condition
15 May 24
DEF 14A
Definitive proxy
22 Apr 24
PRE 14A
Preliminary proxy
12 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Results of Operations and Financial Condition
28 Mar 24
8-K
Departure of Directors or Certain Officers
6 Feb 24
8-K
Entry into a Material Definitive Agreement
23 Jan 24
8-K
Other Events
9 Jan 24
8-K
Regulation FD Disclosure
4 Jan 24
Latest ownership filings
144
Notice of proposed sale of securities
3 May 24
SC 13D/A
IntelGenx Technologies Corp.
3 May 24
4
Life Sciences AG ATAI
3 May 24
4
Christian Angermayer
17 Apr 24
144
Notice of proposed sale of securities
8 Apr 24
144
Notice of proposed sale of securities
5 Apr 24
4
Anne Nagengast Johnson
4 Apr 24
4
Srinivas Rao
4 Apr 24
4
Sahil Kirpekar
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 33.87 mm | 33.87 mm | 33.87 mm | 33.87 mm | 33.87 mm | 33.87 mm |
Cash burn (monthly) | 3.72 mm | 12.67 mm | 8.03 mm | 9.70 mm | 7.52 mm | 7.13 mm |
Cash used (since last report) | 5.92 mm | 20.16 mm | 12.78 mm | 15.43 mm | 11.97 mm | 11.35 mm |
Cash remaining | 27.94 mm | 13.71 mm | 21.09 mm | 18.44 mm | 21.89 mm | 22.52 mm |
Runway (months of cash) | 7.5 | 1.1 | 2.6 | 1.9 | 2.9 | 3.2 |
Institutional ownership, Q4 2023
26.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 1 |
Closed positions | 86 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 999.47 mm |
Total shares | 44.16 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Apeiron Investment | 32.67 mm | $0.00 |
Galaxy Group Funding ECI U | 10.80 mm | $82.38 mm |
Mirae Asset Global Investments | 623.68 k | $879.38 mm |
Hunter Perkins Capital Management | 19.24 k | $27.00 k |
China Universal Asset Management | 19.21 k | $27.00 k |
Strategic Blueprint | 13.50 k | $19.04 mm |
Detalus Advisors | 10.00 k | $14.10 mm |
Westside Investment Management | 2.45 k | $3.46 mm |
Caldwell Sutter Capital | 500.00 | $705.00 k |
Highlander Capital Management | 150.00 | $212.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Apr 24 | Sahil Kirpekar | Common Shares | Sell | Dispose S | No | No | 1.85 | 35,801 | 66.23 k | 64,199 |
2 Apr 24 | Anne Nagengast Johnson | Common Shares | Sell | Dispose S | No | No | 1.85 | 27,410 | 50.71 k | 73,590 |
2 Apr 24 | Srinivas Rao | Common Shares | Sell | Dispose S | No | No | 1.85 | 61,640 | 114.03 k | 113,360 |
News
HC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $15 Price Target
17 May 24
ATAI Life Sciences Q1 EPS $(0.17) Beats $(0.18) Estimate, Cash $18.87M
15 May 24
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
9 May 24
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
17 Apr 24
ATAI Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
17 Apr 24
Press releases
atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
17 Apr 24
Momentum Stocks Alert: DYAI, KAVL, VTAK, NKLA, ATAI Demonstrate Financial Growth and Strategic Advancements
5 Apr 24
Thinking about buying stock in Akebia Therapeutics, Mind Medicine, ATAI Life Sciences, Doma Holdings, or Iterum Therapeutics?
1 Apr 24
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
28 Mar 24
atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
27 Mar 24